Digitale Bibliotheek
Sluiten Bladeren door artikelen uit een tijdschrift
 
Zoeken naar met titel:
ABCDEFGHIJKLMNOPQRSTUVWXYZ

     Tijdschrift beschrijving
       Alle jaargangen van het bijbehorende tijdschrift
         Alle afleveringen van het bijbehorende jaargang
                                       Alle artikelen van de bijbehorende aflevering
 
                             235 gevonden resultaten
nr titel auteur tijdschrift jaar jaarg. afl. pagina('s) type
1 Abstract withdrawn 2019
 127 S1 p. S69
 artikel
2 A case of hyperprogression of lung cancer following atezolizumab Muthukumar, D.
 2019
 127 S1 p. S94
 artikel
3 Achieving the National Optimal Lung Cancer Pathway: the role of the biomedical scientist Ricketts, W.
 2019
 127 S1 p. S63
 artikel
4 Acute kidney injury risk and prevention in patients undergoing treatment for lung cancer Lewis, A.
 2019
 127 S1 p. S49
 artikel
5 Acute radiation induced CT changes after stereotactic ablative body radiotherapy for primary non-small cell lung cancer Saxby, H.
 2019
 127 S1 p. S74
 artikel
6 A framework for systematic clinical evaluation of technical innovations in lung cancer patients treated on the MR-linac (MRL) Cobben, D.
 2019
 127 S1 p. S58-S59
 artikel
7 Age is no barrier to radical chemoradiation in locally advanced non-small cell lung cancer (NSCLC) Gomberg, S.
 2019
 127 S1 p. S78
 artikel
8 Alerting Unscheduled Lung Cancer Admissions: a novel system for monitoring and alerting the lung cancer team to emergency lung cancer admissions Bradley, J.
 2019
 127 S1 p. S4
 artikel
9 A local qualitative study exploring facilitators and barriers to effective lung cancer decision making Adizie, J.
 2019
 127 S1 p. S6
 artikel
10 Analysis of cytomorphology in NSCLC with specific epidermal growth factor (EGFR) mutations Bowden, R.
 2019
 127 S1 p. S2
 artikel
11 Analysis of patients referred to lung cancer MDM due to diagnosis of lung cancer made during an acute emergency admission in South Eastern HSC Trust Jamaludin, J.
 2019
 127 S1 p. S23
 artikel
12 An assessment of the impact of smoking and comorbid conditions on lung cancer outcomes Burke, E.
 2019
 127 S1 p. S56
 artikel
13 An audit into the use of bisphosphonates for patients with non-small cell lung cancer and bone metastases at a tertiary cancer centre Broadbent, R.
 2019
 127 S1 p. S86
 artikel
14 An audit of pulmonary nodule workload and a proposed pathway in response to the recent BTS guidelines Webb, P.
 2019
 127 S1 p. S10
 artikel
15 An audit of sequential chemoradiotherapy for non-small cell lung cancer (NSCLC) at the Leeds Cancer Centre (LCC) Sun, F.
 2019
 127 S1 p. S77-S78
 artikel
16 An audit of thoracic radiotherapy in extensive stage small cell lung cancer delivered as per REST trial protocol Iqbal, M.S.
 2019
 127 S1 p. S82-S83
 artikel
17 An audit on IASLC compliance of lymph nodes dissection and impact on survival after surgery for non-small cell lung cancer De Sousa, P.
 2019
 127 S1 p. S66
 artikel
18 An audit on the outcomes of patients with primary lung cancer treated with stereotactic ablative radiotherapy (SABR) at a single institute between 2013 and 2018 Mccabe, A.
 2019
 127 S1 p. S76
 artikel
19 An audit on the use of osimertinib in T790M EGFR+ patients at West Suffolk Hospital Davis, O.
 2019
 127 S1 p. S40
 artikel
20 An evaluation of targets in lung cancer 2-week-wait pathway: closing the loop to the Quality Improvement Project at Great Western Hospital Swindon Hameed, F.
 2019
 127 S1 p. S21-S22
 artikel
21 An evaluation of the Irish Cancer Society’s 2018 lung cancer awareness campaign Mcnamara, A.
 2019
 127 S1 p. S49-S50
 artikel
22 A project to investigate and compare biopsy methods for lung cancer diagnosis Pink, G.
 2019
 127 S1 p. S24
 artikel
23 Are endobronchial ultrasound-guided transbronchial needle aspiration samples adequate for PD-L1 testing in non-small cell lung cancer? Falconer, W.
 2019
 127 S1 p. S18
 artikel
24 A retrospective analysis of lymphopenia rates during and after sequential and concurrent radical chemoradiotherapy for patients with stage III non-small cell lung cancer (NSCLC) Westley, R.
 2019
 127 S1 p. S80
 artikel
25 A retrospective case-control study to assess the impact of enhanced supportive care for patients with advanced lung cancer Vijeratnam, N.
 2019
 127 S1 p. S64
 artikel
26 A retrospective comparison of frontline platinum in non-squamous non-small-cell lung cancer in North Wales over 9 years Wreglesworth, N.
 2019
 127 S1 p. S32
 artikel
27 A retrospective 12 month audit of all lung cancer patients attending the Acute Oncology Assessment Unit at a Scottish Regional Cancer Centre Devenay, S.
 2019
 127 S1 p. S51-S52
 artikel
28 A review of urgent suspected lung cancer referrals in Edinburgh Royal Infirmary Quinn, T.
 2019
 127 S1 p. S27
 artikel
29 A single centre experience of anti-PDL1 and anti-PD1 agents in treatment of non-small cell lung cancer (NSCLC) Saunders, E.
 2019
 127 S1 p. S44
 artikel
30 A single centre experience of anti-PDL1 and anti-PDL agents in the treatment of thoracic malignancies Choy, J.
 2019
 127 S1 p. S69
 artikel
31 A single centre experience of first-line pembrolizumab in stage IV non-small-cell lung cancer (NSCLC) Denslow, R.
 2019
 127 S1 p. S35
 artikel
32 Assess the benefits of Implementing regular nutritional screening for patients with a lung cancer diagnosis Rushton, C.
 2019
 127 S1 p. S50
 artikel
33 A survey of the practice of stereotactic ablative radiotherapy for lung cancer in the UK on behalf of the Advanced Radiotherapy Technologies Network (ART-NET) Brown, S.
 2019
 127 S1 p. S76
 artikel
34 Attitudes to, and symptom awareness of lung cancer in Ireland: findings from a global consumer poll Mcnamara, A.
 2019
 127 S1 p. S49
 artikel
35 Audit of outcomes of patients with stage III NSCLC (TNM VII) who were treated with radical RT or high-dose palliative radiotherapy between January 2017 and July 2017 Smith, E.
 2019
 127 S1 p. S79
 artikel
36 Audit of stage III non-small cell lung cancer (NSCLC) management in the Essex Cancer Network Reinius, M.
 2019
 127 S1 p. S8
 artikel
37 Author Index 2019
 127 S1 p. S98-S103
 artikel
38 Avoiding cardiac toxicity in patients undergoing curative intent radiotherapy for lung cancer Banfill, K.
 2019
 127 S1 p. S91-S92
 artikel
39 Banf1 as a marker of lung cancer cell sensitivity to cisplatin Plowman, J.
 2019
 127 S1 p. S3
 artikel
40 Brain imaging prior to radical radiotherapy for NSCLC Closier, P.
 2019
 127 S1 p. S15
 artikel
41 Brigatinib in crizotinib-refractory ALK+ non-small cell lung cancer (NSCLC): efficacy updates and exploratory analysis of target lesion response by baseline brain lesion status in the ALTA Trial Kim, D.
 2019
 127 S1 p. S30-S31
 artikel
42 Can the recommended mediastinal staging performance standards for endosonography be met in everyday clinical practice? Barker, A.
 2019
 127 S1 p. S18-S19
 artikel
43 Can ‘Upfront’ PET-CT reduce time to diagnosis in lung cancer target referrals? Verghese, P.
 2019
 127 S1 p. S9
 artikel
44 Case report: station 5 nodal sampling via conventional EBUS in the presence of ROSE Deacon, A.
 2019
 127 S1 p. S93
 artikel
45 Cells and DNA: quality improvement (QI) initiative for molecular tests from cytology samples Bhagwat, P.
 2019
 127 S1 p. S19
 artikel
46 Changes in performance status of lung cancer patients between respiratory and oncology clinics Docherty, C.
 2019
 127 S1 p. S27-S28
 artikel
47 Chloropyramine increases NSCLC sensitivity to cisplatin in a SASH1 dependent manner Burgess, J.
 2019
 127 S1 p. S1-S2
 artikel
48 Clinical outcomes related to smoking status in the era of single-port VATS resection for non-small cell lung cancer Gleeson, H.V.
 2019
 127 S1 p. S90
 artikel
49 Clinical presentation and prognosis of high PD-L1 expressors in non-small cell lung cancer Chin, I.S.
 2019
 127 S1 p. S66
 artikel
50 Collaborative genomics for improved patient care; a lung cancer case report Du Parcq, P.
 2019
 127 S1 p. S2-S3
 artikel
51 Comparing outcomes of patients with epidermal growth factor receptor (EGFR) therapy resistant mutations (EXON 20 and T790M) Enver, M.
 2019
 127 S1 p. S39
 artikel
52 Concurrent chemoradiation in limited stage small cell lung cancer (LS-SCLC): an analysis of survival and toxicity Matthews, S.
 2019
 127 S1 p. S85
 artikel
53 Correlation of standardised uptake value (SUV) on fluorodeoxyglucose positron emission tomography scans with the development of metastatic disease in early-stage lung cancer treated with stereotactic ablative radiotherapy (SABR) Sambasivan, K.
 2019
 127 S1 p. S75-S76
 artikel
54 CT as a tool for endobronchial stent size estimation: a district general hospital experience Sundaralingam, A.
 2019
 127 S1 p. S87
 artikel
55 CT guided percutaneous transthoracic lung biopsy (PTLB), risk of pneumothorax and associated factors Gogokhia, A.
 2019
 127 S1 p. S15-S16
 artikel
56 CT texture analysis as a predictor of effectiveness of second line nivolumab in metastatic non-small cell lung cancer Ladwa, R.
 2019
 127 S1 p. S16-S17
 artikel
57 Defining COMMD4 as an anti-cancer therapeutic target and potential diagnostic biomarker in lung cancer Suraweera, A.
 2019
 127 S1 p. S1
 artikel
58 Determining the factors associated with 1-year survival in small cell lung cancer using national audit, chemotherapy and radiotherapy data Jones, G.
 2019
 127 S1 p. S83-S84
 artikel
59 Determining the feasibility and acceptability of a mobile health application to remotely monitor the symptoms of people with mesothelioma at home Maguire, R.
 2019
 127 S1 p. S87-S88
 artikel
60 Developing a nurse consultant-led immunotherapy services in a district general hospital Muthukumar, D.
 2019
 127 S1 p. S52
 artikel
61 Developing, launching and evaluating a research network for mesothelioma Lenny, C.
 2019
 127 S1 p. S58
 artikel
62 Development of a lung consultant therapy radiographer and the impact on the stereotactic ablative radiotherapy pathway: the Northern Centre for Cancer care (NCCC) Newcastle experience Pickles, R.
 2019
 127 S1 p. S80
 artikel
63 DGH experience of implementing NOLCP: day –3 to 0 Spencer, E.
 2019
 127 S1 p. S25
 artikel
64 Diagnostic yield and safety of EBUS-TBNA: single-centre experience of 500 patients Baty, N.
 2019
 127 S1 p. S20
 artikel
65 Does chemotherapy offer a survival benefit to NSCLC patients with a performance status of 2? Thompson, L.
 2019
 127 S1 p. S48-S49
 artikel
66 Does endobronchial ultrasound (EBUS) fine needle aspirate provide sufficient tissue for molecular markers? Gabriel, L.
 2019
 127 S1 p. S18
 artikel
67 Does molecular analysis alter treatment options for patients in Wolverhampton? Jones, J.
 2019
 127 S1 p. S47-S48
 artikel
68 Does pleural fluid volume influence adequacy of samples for immunohistochemistry or molecular testing? Mccracken, D.
 2019
 127 S1 p. S28
 artikel
69 Do lung cancer outcomes vary by presenting symptom? Aslam, R.
 2019
 127 S1 p. S25-S26
 artikel
70 Do we adequately follow-up extrathoracic lesions identified on PET CT? Mendes, S.
 2019
 127 S1 p. S11
 artikel
71 Early experience from the Plymouth National Optimal Lung Cancer Pathway Snook, S.
 2019
 127 S1 p. S61
 artikel
72 Early proactive referral identifies lung cancer patients with significant palliative care needs Droney, J.
 2019
 127 S1 p. S87
 artikel
73 EBUS in lung cancer staging and diagnosis: service performance across a cancer alliance Mulla, A.
 2019
 127 S1 p. S17
 artikel
74 EBUS-TBNA for the diagnosis of lung parenchymal lesions Singh, R.
 2019
 127 S1 p. S20
 artikel
75 Editorial Board 2019
 127 S1 p. i
 artikel
76 Effectiveness and tolerability of tyrosine kinase inhibitors as treatment for advanced non-small cell carcinoma (NSCLC) in the elderly: a real-world practice three-centre experience Silva, N.
 2019
 127 S1 p. S57-S58
 artikel
77 Efficacy and safety of systemic treatment for older lung cancer patients Gandhi, R.
 2019
 127 S1 p. S70
 artikel
78 Engaging with the National Optimal Lung Cancer Curative Intent Management Pathway: the Bristol experience Teh, E.
 2019
 127 S1 p. S7
 artikel
79 Enhancing sensitivity to platinum-based therapy by suppressing the novel prognostic factor CDCA3 in non- small cell lung cancer Adams, M.
 2019
 127 S1 p. S2
 artikel
80 Establishing a clinical sequencing program for lung cancer in a public hospital O’Byrne, K.
 2019
 127 S1 p. S92
 artikel
81 Estimating renal function in lung cancer patients Gannon, K.
 2019
 127 S1 p. S55-S56
 artikel
82 Evaluating an intervention to improve the two-week wait pathway times for patients with radiologically suspected lung cancers in a district general hospital Dexter, L.
 2019
 127 S1 p. S5
 artikel
83 Evaluation of potential implementation of proposed 28-day cancer waiting time standard at Oxford University Hospitals NHS Foundation Trust Galante, J.R.
 2019
 127 S1 p. S62
 artikel
84 Evidence-based best practices for EGFR and EGFR T790M mutation testing in non-small cell lung cancer (NSCLC) in the UK Welch, L.
 2019
 127 S1 p. S14
 artikel
85 Experience of stereotactic ablative radiotherapy (SABR) in early stage non-small cell lung cancer (NSCLC): an analysis of treatment response and survival outcome Iqbal, M.S.
 2019
 127 S1 p. S73
 artikel
86 Experience with atezolizumab immunotherapy for a patient with non-small cell lung cancer on renal dialysis Mahmood, A.
 2019
 127 S1 p. S95-S96
 artikel
87 Factors influencing treatment selection and prognosis in patients with small cell lung cancer Irshad, S.
 2019
 127 S1 p. S84-S85
 artikel
88 Firming up on pulmonary nodules: a nurse-led approach Graves, J.
 2019
 127 S1 p. S10
 artikel
89 First line anti-PD1 checkpoint inhibitor in the management of patients with advanced non-small cell lung cancer: the Kent Cancer Network experience Angelis, V.
 2019
 127 S1 p. S41
 artikel
90 Follow-up post lung cancer surgery; is there still a role for routine chest radiographs after completion of surveillance CT scans? Rowan, C.
 2019
 127 S1 p. S11
 artikel
91 Glenfield pulmonary neuroendocrine tumour guidelines Weaver, H.
 2019
 127 S1 p. S9-S10
 artikel
92 Gross tumour volume (GTV) delineation on magnetic resonance imaging (MRI), for stage III lung cancer: consensus recommendations needed to ensure contouring consistency Shiarli, A.
 2019
 127 S1 p. S77
 artikel
93 Human single-stranded DNA protein 1 (hSSB1): a new prognostic tool and target for non-small cell lung cancer treatment Boucher, D.
 2019
 127 S1 p. S3
 artikel
94 Human single-stranded DNA protein 1 (hSSB1): a prognostic factor and target for non-small cell lung cancer (NSCLC) treatment Boucher, D.
 2019
 127 S1 p. S17
 artikel
95 Hypofractionated radiotherapy with chemotherapy for stage 3 non-small cell lung cancer: a single centre experience Patibandla, A.
 2019
 127 S1 p. S78
 artikel
96 Iatrogenic tumour seeding (ITS) following a craniotomy for resection of oligometastatic non-small cell lung cancer Malek, A.
 2019
 127 S1 p. S93-S94
 artikel
97 Immune-related adverse events in patients with stage IV non-small cell lung cancer on immunotherapy: experience from the West of Scotland Downham, E.
 2019
 127 S1 p. S42
 artikel
98 Immunotherapy outcomes based on PDL1 expression and tissue origin in NSCLC Khan, S.
 2019
 127 S1 p. S46-S47
 artikel
99 Impact of organisation and specialist service delivery on lung cancer outcomes Adizie, J.
 2019
 127 S1 p. S6-S7
 artikel
100 Impact of radiographer immediate reporting of chest x-rays from general practice on the lung cancer pathway (radioX) Woznitza, N.
 2019
 127 S1 p. S13
 artikel
101 Implementation of National Optimal Lung Cancer Pathway: an early experience Moneke, J.
 2019
 127 S1 p. S11-S12
 artikel
102 Implementation of network-wide mesothelioma MDT and the effect on patient outcomes Hobden, D.
 2019
 127 S1 p. S64
 artikel
103 Implementation of the National Optimal Lung Cancer Pathway: the Nottingham experience Bakewell, F.
 2019
 127 S1 p. S14
 artikel
104 Implementing a low-dose CT screening programme for lung cancer into routine NHS practice: the South Tyneside Model Ross, T.
 2019
 127 S1 p. S23
 artikel
105 Improving outcomes by reducing AKI in lung cancer surgery: introducing MERITS (Multi-centre Evaluation of Renal Impairment in Thoracic Surgery) Naruka, V.
 2019
 127 S1 p. S88
 artikel
106 Improving psychological support for patients with lung cancer and mesothelioma: evaluation of three new nurse-led services Ivey, S.
 2019
 127 S1 p. S51
 artikel
107 Improving the assessment of cardiovascular and respiratory risk factors in radically treated non-small cell lung cancer (NSCLC) using quality improvement methodology Robinson, S.
 2019
 127 S1 p. S55
 artikel
108 Indwelling pleural catheters in Fife: indications and outcomes Bartlett, S.
 2019
 127 S1 p. S29-S30
 artikel
109 Initial evaluation of calcium levels of patients with suspected lung cancer Apthorp, C.
 2019
 127 S1 p. S14-S15
 artikel
110 Intratumoral heterogeneity in PD-L1 expression in pleomorphic lung carcinoma: implications for management of stage III disease Januszewski, A.
 2019
 127 S1 p. S91
 artikel
111 Is a wedge resection a good surgical alternative to lobectomy? Burnside, N.
 2019
 127 S1 p. S88-S89
 artikel
112 Is the current strategy for stratifying patients for targeted therapy use in NSCLC really logical and sustainable? Results from a retrospective study suggest otherwise Moore, D.
 2019
 127 S1 p. S22
 artikel
113 Is tissue from stage 3 NSCLC suitable for biomarker evaluation? Smith, E.
 2019
 127 S1 p. S24-S25
 artikel
114 Large thoracic mass: an unsual presentation of Hodgkin’s lymphoma Niazi, M.
 2019
 127 S1 p. S97
 artikel
115 Laser pulmonary metastasectomy preserves parenchyma: a single-institution study from the United Kingdom Chandarana, K.
 2019
 127 S1 p. S90-S91
 artikel
116 Liverpool Healthy Lung Project second year evaluation: deaths prevented and significant other findings Hill, S.
 2019
 127 S1 p. S92
 artikel
117 Long-term follow-up of patients who had bronchial carcinoid tumours resected in a district general hospital Mccloskey, M.
 2019
 127 S1 p. S63-S64
 artikel
118 Lung adenocarcinoma with ROS1 rearrangement presenting with bilateral organizing pneumonia: a case report Aslam, S.
 2019
 127 S1 p. S95
 artikel
119 Lung cancer in the young: an Irish case series Peters, N.
 2019
 127 S1 p. S96
 artikel
120 Lung cancer pathway: first consultation patient information leaflet Canning, L.
 2019
 127 S1 p. S53
 artikel
121 Lung cancer screening programmes: landscape in China Cheng, Y.
 2019
 127 S1 p. S60-S61
 artikel
122 Lung cancer stigma: addressing it in clinical care Maguire, R.
 2019
 127 S1 p. S72
 artikel
123 Lung cancer 2-week wait referrals, implentation of a new service Smith, R.
 2019
 127 S1 p. S50
 artikel
124 Management recommendations of the lung cancer MDT: are they being followed? Anderson, V.
 2019
 127 S1 p. S65
 artikel
125 Managing elderly patients with lung cancer: is there a need for onco-geriatrics? Brunner, C.
 2019
 127 S1 p. S55
 artikel
126 Managing osteonecrosis of the jaw related to denosumab in patients with lung cancer Wenban, C.
 2019
 127 S1 p. S48
 artikel
127 MARS-2 trial of extended pleurectomy/decortication for malignant mesothelioma: outcomes of screening groups from a surgical centre Sharkey, A.
 2019
 127 S1 p. S30
 artikel
128 Medical thoracoscopy in a DGH: 1-year activity Mackenzie, J.
 2019
 127 S1 p. S28
 artikel
129 Mesothelioma in women: a retrospective case note audit of the occupational history of women diagnosed with malignant mesothelioma in a DGH 2012–2017 Moylan, A.
 2019
 127 S1 p. S29
 artikel
130 Metachronous oligometastatic non-small cell lung cancer: are we selecting the appropriate patients for radical treatment? Cheng, A.
 2019
 127 S1 p. S36
 artikel
131 Missing the boat: real world analysis of second line osimertanib use across North West London Evans, J.
 2019
 127 S1 p. S38
 artikel
132 Modified Lung Immune Predictive Index (mLIPI) as a predictive tool of nivolumab outcomes and immune related adverse events in advanced non-small cell lung cancer (NSCLC) patients Moor, R.
 2019
 127 S1 p. S67-S68
 artikel
133 Multi-modality radical intent treatment in synchronous oligometastatic non-small cell lung cancer: how many patients complete the full treatment regime recommended by the MDT? Cheng, A.
 2019
 127 S1 p. S35-S36
 artikel
134 Multiplex PCR testing of diagnostic lung cancer tissue samples for commonly mutated oncogenes Snead, D.R.
 2019
 127 S1 p. S19
 artikel
135 Nail toxicity in a patient being treated with immune checkpoint inhibitors Botten, J.
 2019
 127 S1 p. S42
 artikel
136 National Lung Cancer Audit patient booklet impact assessment: an evaluation Rodgers, H.
 2019
 127 S1 p. S60
 artikel
137 National Optimal Lung Cancer Pathway implementation: can pathologists comply with turnaround times? Lloyd, K.L.
 2019
 127 S1 p. S3-S4
 artikel
138 National Optimal Lung Cancer Pathway: implementation of a ‘straight to CT’ pathway at NUH Bakewell, F.
 2019
 127 S1 p. S13-S14
 artikel
139 Neuroendocrine cells in the lung: physiology and pathology Pink, G.
 2019
 127 S1 p. S93
 artikel
140 Neutrophil-to-lymphocyte ratio (NLR) trends and treatment response to programmed death/ligand 1 (PD-1/PD-L1) inhibitors in non-small cell lung cancer (NSCLC) Yang, H.
 2019
 127 S1 p. S41-S42
 artikel
141 One size doesn’t fit all. Arguments for and against pathway redesign in a small District General Hospital (DGH) to accommodate the National Optimal Lung Cancer Pathway Bolton, S.
 2019
 127 S1 p. S13
 artikel
142 One-year survival data for lung cancer at the Princess Alexandra NHS Trust Aghadiuno, T.
 2019
 127 S1 p. S68
 artikel
143 Optimising management of EGFR mutant NSCLC through circulating tumour DNA (ctDNA) monitoring Powell, R.
 2019
 127 S1 p. S39
 artikel
144 Optimising nodule management with data from the Lung Screen Uptake Trial Horst, C.
 2019
 127 S1 p. S22
 artikel
145 Outcome of NSCLC (non-small cell lung cancer) patients treated with second line pembrolizumab: experience from the Portsmouth Oncology Centre Gyi, M.M.
 2019
 127 S1 p. S44-S45
 artikel
146 Outcomes after stereotactic ablative body radiotherapy for stage 1 lung cancer Phillips, I.
 2019
 127 S1 p. S72-S73
 artikel
147 Outcomes for patients with NSCLC on immunotherapy treatment (adenocarcinoma) Khalid, F.
 2019
 127 S1 p. S47
 artikel
148 Outcomes for patients with NSCLC on immunotherapy treatment (squamous) Khan, M.
 2019
 127 S1 p. S46
 artikel
149 Overall survival (OS) of real-world patients with stage IIIb/IV non-small cell lung cancer (NSCLC) initiating epidermal growth factor receptor (EGFR) targeted tyrosine kinase inhibitors (TKI) as first-line treatment in England Rigney, U.
 2019
 127 S1 p. S40
 artikel
150 Palliative lung radiotherapy at the Christie: audit of prescribing practice and survival analysis Lewis, T.
 2019
 127 S1 p. S81-S82
 artikel
151 Patient characteristics, imaging and treatment of lung carcinoids in a large teaching hospital Abi Musa Asa’Ari, A.K.A.
 2019
 127 S1 p. S62
 artikel
152 Patient-reported outcome measures for lung cancer in daily clinical use Davies, G.
 2019
 127 S1 p. S67
 artikel
153 Patient reported outcomes (PROs) in patients with extensive-stage small cell lung cancer receiving chemotherapy: a pilot project at a treatment tertiary oncology centre Neal, H.
 2019
 127 S1 p. S53-S54
 artikel
154 Patients with N3 non-small cell lung cancer (NSCLC) treated with radical chemoradiation can expect similar survival to patients with N2 disease Gomberg, S.
 2019
 127 S1 p. S79-S80
 artikel
155 PD-L1 expression in resected non-small cell lung cancer: variation between primary tumour and nodal metastases Haragan, A.
 2019
 127 S1 p. S25
 artikel
156 PD-L1 testing in advance stage lung cancer using cytology samples: suitability and interobserver agreement. How well are we doing? Elshiekh, M.
 2019
 127 S1 p. S20
 artikel
157 Pembrolizumab in non-small cell lung cancer: our experience Rizvi, S.A.
 2019
 127 S1 p. S83
 artikel
158 Pembrolizumab monotherapy for advanced/recurrent non-small cell lung cancer: a Greater Manchester experience Tivey, A.
 2019
 127 S1 p. S45-S46
 artikel
159 Peptide receptor radionuclide therapy for metastatic bronchopulmonary carcinoid tumours: a single ENETS Centre of Excellence experience Evans, J.
 2019
 127 S1 p. S59
 artikel
160 Performance of endobronchial ultrasound-guided transbronchial needle aspiration in PD-L1 testing in patients with NSCLC Perrotta, F.
 2019
 127 S1 p. S21
 artikel
161 Preoperative mediastinal staging throughout Northern Ireland Khan, R.
 2019
 127 S1 p. S18
 artikel
162 Pre-operative uptake of cardiopulmonary exercise test (CPET) in lung cancer surgery in Wolverhampton Zahid, A.
 2019
 127 S1 p. S56-S57
 artikel
163 Pre-triage clinical questionnaire for patients on the National Optimal Lung Cancer Pathway Snook, S.
 2019
 127 S1 p. S61-S62
 artikel
164 Prevalence of incidental interstitial lung disease in the Manchester lung cancer screening pilot Balata, H.
 2019
 127 S1 p. S23-S24
 artikel
165 PRO-CTCAE vs REQUITE: a comparison of two patient reported outcome (PRO) measurement tools in a lung cancer population Jordan, T.
 2019
 127 S1 p. S61
 artikel
166 Prophylactic antibiotics following local anaesthetic thoracoscopy: do they have a role? Ahmed, M.
 2019
 127 S1 p. S68-S69
 artikel
167 Psychological impact of low-dose CT screening in a ‘real-world’ demonstration lung cancer screening pilot Kummer, S.
 2019
 127 S1 p. S68
 artikel
168 Pulmonary Prehabilitation Self Management Programme: a pilot Carlin, M.
 2019
 127 S1 p. S70
 artikel
169 Quality outcome measures for single-port VATS resection of non-small cell lung cancer George, H.A.
 2019
 127 S1 p. S89
 artikel
170 Radial endobronchial ultrasound for the diagnosis of malignant peripheral pulmonary lesions deemed unsuitable for percutaneous CT guided biopsy in a regional ‘Difficult Thoracic Biopsy’ service Tariq, S.
 2019
 127 S1 p. S21
 artikel
171 Radical radiotherapy alone versus chemoradiotherapy for the treatment of stage III (N2) non-small cell lung cancer Mcaleese, J.
 2019
 127 S1 p. S83
 artikel
172 Radiological-pathological correlation of negative CT biopsy results enables high negative predictive value for thoracic malignancy Barnett, J.
 2019
 127 S1 p. S16
 artikel
173 Rapid treatment reponse to pembrolizumab in non- small cell lung cancer (NSCLC) Plant, R.
 2019
 127 S1 p. S94-S95
 artikel
174 Rare double mutations in epidermal growth factor receptor (EGFR) mutant adenocarcinoma of lung Thippu Jayaprakash, K.
 2019
 127 S1 p. S92-S93
 artikel
175 Real world experience of third line docetaxel ± nintedanib post-nivolumab for treatment of metastatic NSCLC in the West of Scotland Rulach, R.
 2019
 127 S1 p. S37-S38
 artikel
176 Real-world experience with nivolumab and atezolizumab toxicities in advanced thoracic malignancies: a single centre experience in the UK Choy, J.
 2019
 127 S1 p. S69-S70
 artikel
177 Real-world outcomes with pembrolizumab in patients with treatment-naive advanced/metastatic NSCLC in the UK: multicentre retrospective observational study Tokaca, N.
 2019
 127 S1 p. S33-S34
 artikel
178 Real world practice patterns for NSCLC patients in an Irish setting: a multi-centre study on targetable gene alterations and PD-L1 expression Kee, W.
 2019
 127 S1 p. S47
 artikel
179 Real world treatment and outcomes in patients with EGFR mutation positive advanced non-small cell lung cancer: the Kent Cancer Network experience Angelis, V.
 2019
 127 S1 p. S39
 artikel
180 Real-world treatment patterns among adults with treatment-naive advanced non-small cell lung (aNSCLC) cancer in Europe: a systematic literature review (SLR) Gara, A.
 2019
 127 S1 p. S32-S33
 artikel
181 Reducing pathway length in lung cancer by multidisciplinary intervention: Wolverhampton Intervention in Lung cancer Daily, ‘The WILD project’ Morgan, A.
 2019
 127 S1 p. S5-S6
 artikel
182 Relationship between body mass index (BMI), body composition and outcomes in patients receiving first line chemotherapy for advanced or metastatic non-small cell lung cancer (NSCLC): a single centre experience Holden, C.
 2019
 127 S1 p. S34-S35
 artikel
183 Resection rates in patients with non-small cell lung cancer and cardiovascular co-morbidities Welch, C.
 2019
 127 S1 p. S54
 artikel
184 Resistance beyond osimertinib Powell, R.
 2019
 127 S1 p. S38
 artikel
185 Results from a prevalence round of LDCT screening for lung cancer in the Lung Screen Uptake Trial Ruparel, M.
 2019
 127 S1 p. S22-S23
 artikel
186 Retrospective analysis of the management of extensive stage small cell lung cancer (SCLC) in patients with a poor performance status Moore, T.
 2019
 127 S1 p. S84
 artikel
187 Review of outcomes for patients with large cell neuroendocrine lung tumours in North East England Gault, A.
 2019
 127 S1 p. S66-S67
 artikel
188 SABR implementation at a regional cancer centre: first-year outcomes and challenges at the Kent Oncology Centre Forner, S.
 2019
 127 S1 p. S75
 artikel
189 Safety of pembrolizumab in patients with non-small cell lung cancer: a real-world study Thakrar, D.B.
 2019
 127 S1 p. S40-S41
 artikel
190 Sequential treatment with afatinib and osimertinib in real-world patients with EGFR mutation-positive advanced NSCLC: the GioTag study Hochmair, M.
 2019
 127 S1 p. S59-S60
 artikel
191 Sequential treatment with afatinib and osimertinib in real-world patients with EGFR mutation-positive advanced NSCLC: the GioTag study Hochmair, M.
 2019
 127 S1 p. S37
 artikel
192 Serum β-hCG in non-small cell lung cancer: a potential marker for early detection and assessing treatment response? A case report Killean, A.
 2019
 127 S1 p. S94
 artikel
193 Sheffield Prospective Single-Port VATS Quality of Life Cohort study (SP2QC) Hocknell, E.
 2019
 127 S1 p. S89-S90
 artikel
194 Short versus long course of palliative radiotherapy for symptom control irradiating chest in lung cancer patients Belikova, H.
 2019
 127 S1 p. S82
 artikel
195 Should smoking cessation be promoted in patients with advanced lung cancer: a literature review Hugh, M.
 2019
 127 S1 p. S52
 artikel
196 Single centre real life experience with first line pembrolizumab in advanced NSCLC in the North West Coast (Lans and South Cumbria) Abdulwahid, D.
 2019
 127 S1 p. S45
 artikel
197 Single-centre retrospective analysis of prognostic scores by the Royal Marsden Hospital (RMH) and the Gustave Roussy Institute (GRIm) in a Nottinghamshire population treated with immunotherapy for advanced non-small cell lung cancer (NSCLC) Lopez Escola, C.
 2019
 127 S1 p. S62-S63
 artikel
198 Smoking cessation: an important, simple and yet forgotten intervention! Hamigi, I.
 2019
 127 S1 p. S72
 artikel
199 Smoking patterns and attitudes to smoking cessation among patients actively receiving anti-cancer treatment Keane, F.
 2019
 127 S1 p. S71-S72
 artikel
200 Stereotactic ablative radiotherapy for non-small cell lung cancer: early experience in Aberdeen Royal Infirmary Laws, K.
 2019
 127 S1 p. S74
 artikel
201 Stereotactic ablative radiotherapy for second primary lung malignancy arising post-pneumonectomy Ariyaratne, H.
 2019
 127 S1 p. S73
 artikel
202 Survival following radical radiotherapy for satellite or synchronous ipsilateral nodules Walls, G.
 2019
 127 S1 p. S81
 artikel
203 Testing of EGFR mutations, ALK translocations and PD-L1 expression in patients diagnosed with adenocarcinoma at Great Western Hospital, Swindon: a re-audit after reflex testing had been declined Gibson, V.
 2019
 127 S1 p. S26
 artikel
204 The ALK project: a real-world national network and database Gomes, F.
 2019
 127 S1 p. S31-S32
 artikel
205 The benefits of web-based clinician-led daily tracking of lung cancer diagnostic pathways Grundy, S.
 2019
 127 S1 p. S9
 artikel
206 The experience of immunotherapy in lung cancer: an audit of immunotherapy use as second-line treatment for metastatic non-small cell lung cancer (NSCLC) in the South Tees region Hairudin, T.
 2019
 127 S1 p. S43
 artikel
207 The experience of immunotherapy in lung cancer: an audit of patients receiving first-line immunotherapy for metastatic small cell lung cancer in South Tees between June 2016 and December 2017 Hairudin, T.
 2019
 127 S1 p. S43
 artikel
208 The financial impact of establishing a comprehensive inpatient smoking cessation service: developing the CURE project in Greater Manchester Mulla, A.
 2019
 127 S1 p. S57
 artikel
209 The impact of a curative intent bundle pathway in a lung cancer service Glynn, P.
 2019
 127 S1 p. S7-S8
 artikel
210 The impact of community-based lung cancer screening on smoking behaviour in a deprived population Traverse-Healy, L.
 2019
 127 S1 p. S71
 artikel
211 The impact of COPD on lung cancer treatment and survival Lin, Y.P.
 2019
 127 S1 p. S27
 artikel
212 The impact of intra-thoracic anatomical changes upon the delivery of lung stereotactic ablative radiotherapy Brown, S.
 2019
 127 S1 p. S74-S75
 artikel
213 The impact of route of referral on treatment intent and survival in patients with lung cancer: results of a local survey Woodhouse, L.
 2019
 127 S1 p. S65-S66
 artikel
214 The impact of the Lung Cancer Navigator on the MDT Hugh, M.
 2019
 127 S1 p. S50-S51
 artikel
215 The North Trent experience of the use of first line pembrolizumab in stage IIIB/IV non-small cell lung cancer Elmushraf, R.
 2019
 127 S1 p. S43
 artikel
216 The role of PCI in extensive stage small cell lung cancer treated with palliative chemotherapy and consolidative thoracic radiotherapy Iqbal, M.S.
 2019
 127 S1 p. S85-S86
 artikel
217 The tsunami that is immunotherapy in NSCLC Charalambous, M.
 2019
 127 S1 p. S46
 artikel
218 The utility of cfDNA as a diagnostic tool in the management of EGFR-mutated non-small cell lung cancer (NSCLC): our regional off-study experience Nageshwaran, S.
 2019
 127 S1 p. S15
 artikel
219 The value of the lung cancer nurse specialist in the development and implimentation of the local optimal lung cancer pathway Bennett, A.
 2019
 127 S1 p. S51
 artikel
220 Tomotherapy and tarceva: surviving ten years with stage IV lung cancer Keshwani, K.
 2019
 127 S1 p. S96-S97
 artikel
221 To talc or not to talc: can thoracoscopists accurately predict malignancy and trapped lung? Holme, J.
 2019
 127 S1 p. S28-S29
 artikel
222 Toxicities and acute oncology service demand of patients receiving immunotherapy for NSCLC: single centre experience Closier, P.
 2019
 127 S1 p. S48
 artikel
223 Treatment patterns and outcomes for limited stage small cell lung cancer treated with chemoradiotherapy Sim, D.
 2019
 127 S1 p. S85
 artikel
224 Triage of suspected cancer referrals as part of the National Optimal Lung Cancer Pathway (NOLCP): is this acceptable to patients? Brackenborough, K.
 2019
 127 S1 p. S8
 artikel
225 Trustwide audit of percutaneous lung biopsy (PLB): delays and complication rates Pegg, E.
 2019
 127 S1 p. S16
 artikel
226 Tumour shape features are not the prognostic factors they appear to be Davey, A.
 2019
 127 S1 p. S80-S81
 artikel
227 Understanding current lung cancer service to drive improvements towards achieving the national optimal lung cancer pathway at a busy district general hospital El-Nayal, A.
 2019
 127 S1 p. S4-S5
 artikel
228 Understanding patients’ psychological responses to low-dose CT lung cancer screening to inform the development of a training resource for nurses Kummer, S.
 2019
 127 S1 p. S53
 artikel
229 University Hospitals North Midlands outcomes from sequential chemo-radiotherapy in non-small cell lung cancer Best, J.
 2019
 127 S1 p. S77
 artikel
230 Usage and knowledge of electronic cigarettes (e-cigs) in young people in Manchester Harris, M.
 2019
 127 S1 p. S71
 artikel
231 Use of pembrolizumab in previously treated patients with advanced non-small cell lung cancer: the Kent Cancer Network experience Hunter, S.
 2019
 127 S1 p. S36-S37
 artikel
232 Video-assisted thoracoscopicsurgical procedures using laryngeal mask (LMA) spontaneous ventilation anaesthesia: an early experience of a novel anaesthetictechnique Hussain, A.
 2019
 127 S1 p. S88
 artikel
233 Volumetric analysis for pulmonary nodules surveillance: a retrospective audit Rowan, C.
 2019
 127 S1 p. S12
 artikel
234 What do people living with and surviving lung cancer want and need from the Recovery Package? Roberts, J.
 2019
 127 S1 p. S52-S53
 artikel
235 Yield of pleural fluid cytology in those with risk factors for malignant pleural mesothelioma Trappes-Lomax, C.
 2019
 127 S1 p. S29
 artikel
                             235 gevonden resultaten
 
 Koninklijke Bibliotheek - Nationale Bibliotheek van Nederland